Bordignon C, Vago L, Oliveira G, Ghio D, Lupo Stanghellini M, Peccatori J, Bondanza A, Lambiase A, Ciceri F, Bonini F
Thymic renewal and antileukemic effect in adults after haploidentical transplantation and suicide gene therapy
J Clin Oncol 28:7s, 2010 (suppl; abstr 6534)

Ciceri F, Bonini C, Stanghellini MT, Bondanza A, Traversari C, Salomoni M, Turchetto L, Colombi S, Bernardi M, Peccatori J, Pescarollo A, Servida P, Magnani Z, Perna SK, Valtolina V, Crippa F, Callegaro L, Spoldi E, Crocchiolo R, Fleischhauer K, Ponzoni M, Vago L, Rossini S, Santoro A, Todisco E, Apperley J, Olavarria E, Slavin S, Weissinger EM, Ganser A, Stadler M, Yannaki E, Fassas A, Anagnostopoulos A, Bregni M, Stampino CG, Bruzzi P, Bordignon C.
Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study.
Lancet Oncol. 2009 May 1;10:489-500
 
Lupo Stanghellini MT, Ciceri F, Bonini C, Bondanza A, Traversari C, Salomoni M, Turchetto L, Colombi S, Bernardi M,  Peccatori J, Pescarollo A, Servida P, Magnani Z, Perna SK , Valtolina V, Crippa F, Callegaro L, Spoldi E, Crocchiolo R, Fleischhauer K, Ponzoni M, Vago L, Santoro A, Todisco E, Apperley J, Olavarria E, Slavin S, Weissinger EM, Hertenstein B, Stadler M, Yannaki E, Anagnostopoulos A, Gallo Stampino C, Bregni M, Bruzzi P and Bordignon C
Early and effective immune-recovery by gene-engineered lymphocytes after haploidentical transplantation for leukemia abate late transplant mortality.
Blood (ASH Annual Meeting Abstracts) 2008 112: Abstract 353

Ciceri F, Bonini C, Marktel S, Zappone E, Servida P, Bernardi M, Pescarollo A, Bondanza A, Peccatori J, Rossini S, Magnani Z, Salomoni M, Benati C, Ponzoni M, Callegaro L, Corradini P, Bregni M, Traversari C, and Bordignon C
Antitumour effects of HSV-TK-engineered donor lymphocytes after allogeneic stem-cell transplantation
Blood, 1 June 2007; 109:11, 4698-4707

Traversari C, Marktel S, Magnani Z, Mangia P, Russo V, Ciceri F, Bonini C, and Bordignon C
The potential immunogenicity of the TK suicide gene does not prevent full clinical benefit associated with the use of TK-transduced lymphocytes in HSCT for hematological malignancies
Blood, 1 June 2007; 109:11, 4708-4715
 
Ciceri F, Bonini C, Lupo Stanghellini MT, Bondanza A, Magnani Z, Perna S, Bernardi M, Peccatori J, Pescarollo A, Servida P, Crippa F, Callegaro L, Salomoni M, Turchetto L, Toma S, Bruzzi P, Castagna L, Santoro A, Apperley J, Slavin S, Colombi S, Gallo Stampino C, Bregni M and Bordignon C.
HSV TK engineered donor lymphocytes add backs reduce late mortality and improve survival of high risk acute leukaemia after haplo HSCT: results of a phase II multicenter trial.
Blood( ASH Annual Meeting Abstracts) 2005 106: Abstract 439.

Ciceri F, Bonini C, Gallo Stampino C and Bordignon C.
Modulation of GvHD by suicide-gene transduced donor T lymphocytes: clinical applications in mismatched transplantation.
Cytotherapy 2005, 7(2):144-9.

Bondanza A, Valtolina V, Magnani Z, Ponzoni M, Fleischhauer K, Bonyhadi M, Traversari C, Sanvito F, Toma S, Radrizzani M, La Seta-Catamancio S, Ciceri F, Bordignon C, Bonini C.
Suicide gene therapy of graft-versus-host disease induced by central memory human T lymphocytes.
Blood. 2005, Nov 17; [Epub ahead of print].

Bonini C, Grez M, Traversari C, Ciceri F, Marktel S, Ferrari G, Dinauer M, Sadat M, Aiuti A, Deola S, Radrizzani M, Hagenbeek A, Apperley J, Ebeling S, Martens A, Kolb HJ, Weber M, Lotti F, Grande A, Weissinger E, Bueren JA, Lamana M, Falkenburg JH, Heemskerk MH, Austin T, Kornblau S, Marini F, Benati C, Magnani Z, Cazzaniga S, Toma S, Gallo-Stampino C, Introna M, Slavin S, Greenberg PD, Bregni M, Mavilio F, Bordignon C.
Safety of retroviral gene marking with a truncated NGF receptor.
Nat Med. 2003, Apr; 9(4):367-9.

Marktel S, Magnani Z, Ciceri F, Cazzaniga S, Riddell SR, Traversari C, Bordignon C, Bonini C.
Immunologic potential of donor lymphocytes expressing a suicide gene for early immune reconstitution after hematopoietic T-cell-depleted stem cell transplantation.
Blood. 2003 Feb 15;101(4):1290-8. Epub 2002 Oct 03.

Verzeletti S, Bonini C, Marktel S, Nobili N, Ciceri F, Traversari C, Bordignon C.
Herpes simplex virus thymidine kinase gene transfer for controlled graft-versus-host disease and graft-versus-leukemia: clinical follow-up and improved new vectors.
Hum Gene Ther. 1998 Oct 10;9(15):2243-51.

Bonini C, Ferrari G, Verzeletti S, Servida P, Zappone E, Ruggieri L, Ponzoni M, Rossini S, Mavilio F, Traversari C, Bordignon C.
HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia.
Science. 1997 Jun 13;276(5319):1719-24.

Bordignon C, Bonini C, Verzeletti S, Nobili N, Maggioni D, Traversari C, Giavazzi R, Servida P, Zappone E, Benazzi E, et al.
Transfer of the HSV-tk gene into donor peripheral blood lymphocytes for in vivo modulation of donor anti-tumor immunity after allogeneic bone marrow transplantation.
Hum Gene Ther. 1995 Jun;6(6):813-9.











 

Santoro A, Pressiani T, Citterio G, Rossoni G, Donadoni G, Pozzi F, Rimassa L, Personeni N, Bozzarelli S, Rossoni G, Colombi S, De Braud FG, Caligaris-Cappio F, Lambiase A, Bordignon C.

Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma

Br J Cancer 2010 Aug 17 [Pubbl. anteprima online]

Santoro A, Rimassa L, Sobrero AF, Citterio G, Sclafani F, Carnaghi C, Pessino A, Caprioni F, Andretta V, Tronconi MC, Finocchiaro G, Rossoni G, Zanoni A, Miggiano C, Rizzardi GP, Traversari C, Caligaris-Cappio F, Lambiase A, Bordignon C

Phase II study of NGR-hTNF, a selective vascular targeting agent, in patients with metastatic colorectal cancer after failure of standard therapy

Eur J Cancer. 2010 Aug 12 [Pubbl. anteprima online]

Simonelli M, Santoro A.,  Zucali P.A., Rimassa L., De Vincenzo F,  Pressiani T, Tronconi M.C, Carnaghi C, Lambiase A.,  Bordignon C
Phase I study of NGR-hTNF administered at high doses in refractory patients with solid tumors.
J Clin Oncol 28, 2010 (suppl; abstr e13091)

Gregorc V, Novello S, Santoro A, Grossi F, Giaj Levra M, Cavina R, Viganò M, Caligaris-Cappio F, Lambiase A, Bordignon C
Phase II study of NGR-hTNF, a vascular targeting agent, in combination with doxorubicin in patients with relapsed small cell lung cancer (SCLC)
J Clin Oncol 28, 2010 (suppl; abstr e18043)

Di Benedetto M, Bennicelli E, Andretta V, Pessino A, Guglielmi A, Sciallero MS,  Sobrero AF, Fornarini G, Lambiase A, Bordignon C
Two doses of NGR-hTNF combined with capecitabine/oxaliplatin (XELOX) in colorectal cancer (CRC) patients failing standard regimens: A phase II study
J Clin Oncol 28, 2010 (suppl; abstr e14077)

Rossoni G, Gregorc V, Citterio G, Spreafico A, Donadoni G., Vitali G, Borri A, Caligaris-Cappio F., Lambiase A, Bordignon C
Predictive potential of angiogenic plasma biomarkers (PBs) in phase I trial with NGR-hTNF
J Clin Oncol 28, 2010 (suppl; abstr e13612)

Gregorc V, Zucali PA, Santoro A, Ceresoli G.L., Citterio G., De Pas TM, Zilenmbo N, De Vincenzo F, Simonelli M, Rossoni G, Spreafico A, Viganò MG, Fontana F, De Braud FG, Bajetta E., Caligaris-Cappio F, Bruzzi P, Lambiase A, Bordignon C.
Phase II Study of Asparagine-Glycine-Arginine- Human Tumor Necrosis factor alpha, a selective vascular targeting agent, in priviously treated patients with malignant pleural mesothelioma.
Journal of Clinical Oncology (2010), Vol 28, n. 15:2604-2611

Van Laarhoven H, Fiedler W, Desar I, van Asten J, Maréaud S, Laombe D, Govaerts J, Lasch P, Timmer-Bonte J, Lambiase A, Bordignon C, Punt C, Heerschap A, van Herpen C.
Phase I Clinical and Magnetic Resonance Imaging Study of the Vascular Agent NGR-hTNF in patients with advanced cancers (European Organization for Research and treatment of Cancer Study 16041)
Clin. Cancer Res. 2010 Feb 15;16(4):1315-23.

Gregorc V, Citterio G, Vitali G, Spreafico A, Scifo P, Borri A, Donadoni G, Rossoni G, Corti A, Caligaris-Cappio F, Maschio AD, Esposito A, De Cobelli F, Dell'acqua F, Troysi A, Bruzzi P, Lambiase A, Bordignon C.
Defining the optimal biological dose of NGR-hTNF, a selective vascular targeting agent, in advanced solid tumours.
Eur J Cancer 2010 Jan;46(1):198-206

Citterio G, De Braud F, Gregorc V, De Pas TM, Scalamogna R, Boselli S, Giovannini M, Caligaris Cappio F, Lambiase A, Bordignon C.
Phase I study of NGR-hTNF, a vascular targeting agent (VTA), in combination with cisplatin in refractory patients with solid tumours.
European Journal of Cancer Supplements, Volume 7, September 2009, 128.

Gregorc V, Ceresoli GL, Zucali PA, De Braud FG, Bajetta E, santoro A, Viganò MG, Caligaris Cappio F, Lambiase A, Bordignon C.
NGR-hTNF, a vascular targeting agent (VTA), in previously treated patients with malignant pleural mesothelioma (MPM): a phase II study.
European Journal of Cancer Supplements, Volume 7, September 2009, 508

Rimassa L, Santoro A, Sobrero A, Sclafani F, Gregorc V, Andretta V, Tronconi MC, Caligaris Cappio F, Lambiase A, Bordignon C.
NGR-hTNF, a vascular rargeting agent (VTA), administered as single agent in patients with colorectal cancer (CRC) failing standard regimens: a Phase II study.
European Journal of Cancer Supplements, Volume 7, September 2009, 340

Sobrero AF, Pessino A, Andretta V, Bennicelli E, Fornarini G, Caprioni F, Comandini D, Orsino L, Lambiase A, Bordignon C.
Phase II study of two doses of NGR-hTNF, a vascular targeting agent (VTA), combined with Capecitabine/oxaliplatin (Xelox) in colorectal cancer (CRC) patients failing standard regimens.
European Journal of Cancer Supplements, Volume 7, September 2009, 341

Santoro A, Citterio G, Pressiani T, Gregorc V, Rimassa L, De Braud FG, Rossoni G, Caligaris Cappio F, Lambiase A, Bordignon C.
Phase II study of NGR-hTNF, a selective vascular targeting agent (VTA), in previously treated patients with advanced hepatocellular carcinoma (HCC).
European Journal of Cancer Supplements, Volume 7, September 2009, 395

Gregorc V, Santoro A, Bennicelli E, Punt CJA, Citterio G, Timmer-Bonte JNH, Caligaris Cappio F, Lambiase A, Bordignon C, van Herpen CML
Phase Ib study of NGR–hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumours
British Journal of Cancer (2009) 101, 219–224 
 
Gregorc V, de Braud F, De Pas TM, Citterio G, Scalamogna R, Boselli S, Giovannini M, Caligaris-Cappio F, Lambiase A, Bordignon C.
Phase Ib study to define the optimal low dose of NGR-hTNF, a novel vascular targeting agent (VTA), in combination with cisplatin in patients with solid tumours (Abstract 483P)
Annals of Oncology, Volume19 Supplement 8 September 2008:viii119.

Citterio G, Santoro A, Pressiani T, Scalamogna R, Gregorc V, Rossoni G, Donadoni G, Caligaris-Cappio F, Lambiase A, Bordignon C.
Safety and antitumor activity of NGR-hTNF, a selective vascular targeting agent (VTA), administered at low dose in pre-treated patients (pts) with hepatocellular carcinoma (HCC): preliminary results of a Phase II trial (Abstract 546P)
Annals of Oncology, Volume19 Supplement 8 September 2008:viii178.

Rimassa L, Sobrero A, Santoro A, Andretta V, Gregorc V, Sclafani F, Caprioni F, Caligaris-Cappio F, Lambiase A, Bordignon C.
Phase II study of NGR-hTNF, a novel vascular targeting agent (VTA), administered as single agent at low dose in patients (pts) with colorectal cancer (CRC) refractory to standard regimens (Abstract 397P)
Annals of Oncology, Volume19 Supplement 8 September 2008:viii136.

Ceresoli GL, Gregorc V, Zucali PA, Noberasco C, Bajetta E, Santoro A, Viganò MG, Caligaris-Cappio F, Lambiase A, Bordignon C.
Phase II clinical trial of NGR-hTNF, a novel vascular targeting agent (VTA), as second-line therapy in malignant pleural mesothelioma (MPM) (Abstract 334P)
Annals of Oncology, Volume19 Supplement 8 September 2008:viii119
 
Gallo-Stampino C., Rizzardi G., Toma S., Corti A., Scifo P., Citterio G.,  Gregorc V., Del Maschio A., Caligaris-Cappio F.,  Bordignon C.
Safety and anticancer activity of low dose regimen of NGRhTNF, a new vascular targeting agent, in solid advanced malignancies (NGR002 phase I trial)
Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 25, No 18S (June 20 Supplement), 2007: 3540

Rizzardi G.,  Gregorc V., Vitali G., Gallo Stampino C., van Herpen C., Santoro A., Sobrero A., Punt K., Caligaris-Capio F., Bordignon C.
Optimal safety profile and anticancer activity of NGRhTNF coupled with doxorubicin (NGR003 modified phase I combo trial).
Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 25, No 18S (June 20 Supplement), 2007: 14056

Heerschap A., Fiedler W., Marreaud S., van Laarhoven H., Govaerts A., Peters M., Toma S., Bordignon C., Punt K.,  Van Herpen C. EORTC New Drug Development Group
A phase I study of NGR-TNF, a novel vascular targeting agent, in patients with refractory solid tumors
Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 25, No 18S (June 20 Supplement), 2007: 14074

Van Laarhoven H., Fiedler W., Desar I. M., van Asten S., Marreaud S., Belli R., Bordignon C., Heerschap A., Punt C. J., van Herpen C. M., on behalf of the EORTC, former New Drug Development
Phase I and DCE-MRI evaluation of NGR-TNF, a novel vascular targeting agent, in patients with solid tumors (EORTC 16041)
Journal of Clinical Oncology 26: 2008 (May 20 suppl; abstr 3521)

De Braud F. G., Gregorc V., De Pas T. M., Citterio G., Scalamogna R., Boselli S., Giovannini M., Caligaris- Cappio F., Lambiase A., Bordignon C.
A phase I study to define the optimal low dose of NGR-hTNF, a novel vascular targeting agent (VTA), in combination with cisplatin in patients (pts) with solid tumors
Journal of Clinical Oncology, 2008 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 26, No 15S (May 20 Supplement), 2008: 14647

Citterio G., Santoro A., Scalamogna R., Pressiani T., Gregorc V., Rossoni G., Donadoni G., Caligaris-Cappio F., Lambiase A, Bordignon C.
A phase II study of NGR-hTNF, a novel vascular targeting agent (VTA), administered as single agent at low dose in pretreated patients (pts) with advanced hepatocellular carcinoma (HCC)
Journal of Clinical Oncology, 2008 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 26, No 15S (May 20 Supplement), 2008: 15544

Santoro A., Andretta V., Gregorc V., Rimassa L., Bennicelli E., Sclafani F., Caprioni F., Caligaris-Cappio F., Lambiase A., Bordignon C.
A phase II study of NGR-hTNF, a novel vascular targeting agent (VTA), administered as single agent at low dose in patients (pts) with colorectal cancer (CRC) refractory to standard regimens
Journal of Clinical Oncology, 2008 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 26, No 15S (May 20 Supplement), 2008: 4110

Gregorc V., Zucali P., Ceresoli G. L., Noberasco C., Bajetta E., Santoro A., Viganò M. G., Caligaris-Cappio F., Lambiase A., Bordignon C.
NGR-hTNF, a novel vascular targeting agent (VTA), as second-line therapy in malignant pleural mesothelioma (MPM): Preliminary results of multicenter phase II study
Journal of Clinical Oncology, 2008 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 26, No 15S (May 20 Supplement), 2008: 8099

Sacchi A, Gasparri A, Gallo Stampino C, Toma S, Curnis F and Corti A.
Synergistic Antitumor Activity of Cisplatin, Paclitaxel, and Gemcitabine with Tumor Vasculature-Targeted Tumor Necrosis Factor-alpha.
Clin Cancer Res. 2006, Jan1;12(1)):175-82.

Van Laarhoven HWM, Gambarota G, Heerschaap A, Lok J, Verhagen J, Corti A, Toma S, Gallo Stampino C, Van Der Kogel A and Punt C J.
Effects of the tumor vasculature targeting agent NGR-TNF on the tumor microenvironment in murine lymphomas.
Invest New Drugs. 2005, Dec 23; [Epub ahead of print] .

Di Matteo P, Curnis F, Longhi R, Colombo G, Sacchi A, Crippa L, Protti MP, Ponzoni M, Toma S, Corti A.
Immunogenic and structural properties of the Asn-Gly-Arg (NGR) tumor neovasculature-homing motif.
Mol Immunol. 2005, Dec 6; [Epub ahead of print].

Curnis F, Gasparri A, Sacchi A, Cattaneo A, Magni F, Corti A.
Targeted delivery of IFNgamma to tumour vessels uncouples anti-tumour from counter regulatory mechanisms.
Cancer Res. 2005, 65(7):2906-13.

Corti A, Ponzoni M.
Tumour vascular targeting with tumour necrosis factor alpha and chemotherapeutic drugs.
Ann N Y Acad Sci. 2004, 1028:104-12.

Curnis F, Sacchi A, Corti A.
Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration.
J Clin Invest. 2002 Aug;110(4):475-82.

Curnis F, Arrigoni G, Sacchi A, Fischetti L, Arap W, Pasqualini R, Corti A.
Differential binding of drugs containing the NGR motif to CD13 isoforms in tumor vessels, epithelia, and myeloid cells.
Cancer Res. 2002 Feb 1;62(3):867-74.

Curnis F, Sacchi A, Borgna L, Magni F, Gasparri A, Corti A.
Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13).
Nat Biotechnol. 2002 Nov;18(11):1185-90.

Porcellini S, Gubinelli F, Alberici L, Piovani BM, Rizzardi GP, Bovolenta C.
Chim3 confers survival advantage to CD4+ T cells upon HIV-1 infection by preventing HIV-1 DNA integration and HIV-1-induced G2 cell cycle delay.
Blood. 2010, May 20; 115 (20): 4021-9

Aiuti A, Cattaneo F, Galimberti s, Benninghoff U, cassani B, callegaro L, Scaramuzza S, Andolfi G, Mirolo M, Brigida I, Tabucchi A, Carlucci F, Eibl M, Akel M, Slavin S, Al-Mousa H, Al Ghonaium A, Ferster A, Duppenthaler A, Notarangelo l, Wintergerst U, Buckley R, Bregni M, Marktel S, Valsecchi MG, Rossi P, Ciceri F, Maniero R, Bordignon C, Roncarolo MG
Gene therapy for Immunodeficiency Due to Adenosine Deaminase Deficiency.
N Engl J Med. 2009 Jan 29;360(5):447-58.
 
Fontana R, Bregni M, Cipponi A, Raccosta L, Rainelli C, Maggioni D, Lunghi F, Ciceri F, Mukenge S, Doglioni C, Colau D, Coulie PG, Bordignon C, Traversari C, Russo V.
Peripheral blood lymphocytes genetically modified to express the self/tumor antigen MAGE-A3 induce antitumor immune responses in cancer patients.
Blood. 2009 Feb 19;113(8):1651-60

Porcellini S, Alberici L, Gubinelli F, Lupo R, Olgiati C, Rizzardi GP, Bovolenta C.
The F12-Vif derivative Chim3 inhibits HIV-1 replication in CD4+T lymphocytes and CD34+-derived macrophages by blocking HIV-1 DNA integration.
Blood. 2009 Apr 9;113(15):3443-52

Spitaleri A, Mari S, Curnis F, Traversari C, Longhi R, Bordignon C, Corti A, Rizzardi GP, Musco G.
Structural basis for the interaction of isoDGR with the RGD-binding site of aVß3 integrin.
J Biol Chem (2008) 283, 19757-68 
 
Gasparri AM, Jacchetti E, Colombo B, Sacchi A, Curnis F, Rizzardi GP, Traversari C, Rizzardi GP, Corti A.
Critical role of indoleamine 2,3 dioxygenase in tumor resistance to repeated treatments with targeted IFNgamma.
Mol Cancer Ther (2008) 7, 3859-66 
 
Curnis F,Sacchi A, Gasparri A, Longhi R, Bachi A, Doglioni C, Bordignon C, Traversari C, Rizzardi GP, Corti A.
Isoaspartate-glycine-arginine: a new tumor vasculature-targeting motif.
Cancer Res (2008) 68, 7073-82 
 
Russo V, Cipponi A, Raccosta L, Rainelli C, Fontana R, Maggioni D, Lunghi F, Mukenge S, Ciceri F, Bregni M, Bordignon C, Traversari C.
Lymphocytes genetically modified to express tumor antigens target DCs in vivo and induce antitumor immunity
J Clin Invest. 2007 Oct;117(10):3087-96

Di Nunzio F, Piovani B, Cosset FL, Mavilio F, Stornaiuolo A.
Transduction of human hematopoietic stem cells by lentiviral vectors pseudotyped with the RD114-TR chimeric envelope glycoprotein.
Hum Gene Ther (2007). Sept: 18 (9):811-20

Vallanti G, Lupo R, Federico M, Mavilio F, and Bovolenta C.
T Lymphocytes Transduced with a Lentiviral Vector Expressing F12-vif Are Protected from HIV-1 Infection in an APOBEC3G-Independent Manner.
Mol Ther 2005, 12: 697-706.

Curnis F, Gasparri A, Sacchi A, Cattaneo A, Magni F, Corti A.
Targeted delivery of IFNgamma to tumour vessels uncouples anti-tumour from counter regulatory mechanisms.
Cancer Res. 2005, 65(7):2906-13.

Rizzardi GP, Nozza S, Turchetto L, Harari A, Tambussi G, Salomoni M, Crippa F, Rusconi V, Toma S, Pantaleo G, Lazzarin A, and Bordignon C.
Feasibility of a stem cell gene therapy approach with nonmyeloablative conditioning in patients with HIV-1 infection.
Blood (ASH Annual Meeting Abstracts) 2004; 104: Abstract # 412 .

Bovolenta, C.
Blocking HIV-1 Vif restores a natural mechanism of intracellular antiviral defense.
Curr Drug Targets Immune Endocr Metabol Disord 2004, 4: 257-63.

Bordignon C, Roncarolo MG.
Therapeutic applications for hematopoietic stem cell gene transfer.
Nat Immunol 2002; 3:318-21.

Aiuti A, Slavin S, Aker M, et al.
Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning.
Science 2002; 296:2410-3.

Russo V, Tanzarella S, Dalerba P, Rigatti D, Rovere P, Villa A, Bordignon C, Traversari C.
Dendritic cells acquire the MAGE-3 human tumor antigen from apoptotic cells and induce a class I-restricted T cell response.
Proc Natl Acad Sci U S A. 2000 Feb 29;97(5):2185-90.